IRIS Institutional Research Information System - OPENBS Open Archive UniBS

MALAGOLA, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 19.955
AS - Asia 12.722
EU - Europa 9.525
SA - Sud America 2.624
AF - Africa 277
Continente sconosciuto - Info sul continente non disponibili 21
OC - Oceania 20
Totale 45.144
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 19.595
SG - Singapore 4.574
CN - Cina 4.159
UA - Ucraina 2.364
BR - Brasile 2.151
HK - Hong Kong 1.448
DE - Germania 1.384
IT - Italia 1.341
VN - Vietnam 881
PL - Polonia 868
FI - Finlandia 807
FR - Francia 652
GB - Regno Unito 494
TR - Turchia 480
RU - Federazione Russa 464
IE - Irlanda 393
IN - India 365
SE - Svezia 296
BD - Bangladesh 183
AR - Argentina 171
CA - Canada 155
MX - Messico 122
IQ - Iraq 116
ZA - Sudafrica 98
NL - Olanda 87
EC - Ecuador 78
ES - Italia 73
ID - Indonesia 69
CZ - Repubblica Ceca 64
JP - Giappone 64
CO - Colombia 63
SA - Arabia Saudita 57
AT - Austria 54
VE - Venezuela 48
PK - Pakistan 46
BE - Belgio 45
UZ - Uzbekistan 45
PY - Paraguay 38
MA - Marocco 34
JO - Giordania 31
KE - Kenya 24
AE - Emirati Arabi Uniti 23
EG - Egitto 23
IL - Israele 23
NG - Nigeria 23
CL - Cile 20
EU - Europa 20
PE - Perù 20
UY - Uruguay 20
AU - Australia 18
JM - Giamaica 18
LT - Lituania 18
DZ - Algeria 17
DK - Danimarca 15
IR - Iran 14
MU - Mauritius 14
PT - Portogallo 14
TN - Tunisia 14
AZ - Azerbaigian 13
DO - Repubblica Dominicana 13
ET - Etiopia 13
GR - Grecia 13
MY - Malesia 13
TH - Thailandia 13
OM - Oman 12
PH - Filippine 12
KZ - Kazakistan 11
NP - Nepal 11
BO - Bolivia 10
CR - Costa Rica 10
HN - Honduras 10
PA - Panama 10
AL - Albania 9
BG - Bulgaria 9
KG - Kirghizistan 9
PS - Palestinian Territory 9
SN - Senegal 9
KR - Corea 8
CH - Svizzera 7
RO - Romania 7
BA - Bosnia-Erzegovina 6
RS - Serbia 6
AM - Armenia 5
EE - Estonia 5
HU - Ungheria 5
LK - Sri Lanka 5
LV - Lettonia 5
HR - Croazia 4
KW - Kuwait 4
LB - Libano 4
NI - Nicaragua 4
SK - Slovacchia (Repubblica Slovacca) 4
TT - Trinidad e Tobago 4
BB - Barbados 3
CI - Costa d'Avorio 3
CU - Cuba 3
GT - Guatemala 3
GY - Guiana 3
NO - Norvegia 3
SV - El Salvador 3
Totale 45.108
Salva come PNG Salva come JPEG
Città #
Singapore 2.339
Woodbridge 2.001
Jacksonville 1.616
Ashburn 1.597
Fairfield 1.565
Hong Kong 1.442
Houston 1.344
Ann Arbor 1.125
San Jose 852
Warsaw 848
The Dalles 776
Princeton 736
Cambridge 734
Wilmington 730
Beijing 666
Seattle 633
Chandler 629
Nanjing 539
New York 502
Helsinki 412
Lauterbourg 389
Dublin 387
Los Angeles 364
Istanbul 352
Ho Chi Minh City 279
Dallas 278
Munich 271
Des Moines 256
Brescia 243
Nanchang 233
São Paulo 205
Hanoi 186
Milan 166
Buffalo 160
Changsha 150
Moscow 148
Redondo Beach 143
Shanghai 134
Tianjin 131
Jinan 129
Shenyang 123
Hebei 118
Dearborn 110
San Diego 108
San Francisco 105
Santa Clara 91
Turku 89
Boardman 88
Chicago 88
Council Bluffs 87
Hangzhou 87
Jiaxing 86
Orem 77
London 73
Kunming 67
Brooklyn 64
Kocaeli 64
Rome 64
Nuremberg 61
Guangzhou 58
Rio de Janeiro 56
Verona 56
Ningbo 55
Tokyo 55
Denver 54
Frankfurt am Main 54
Brasília 53
Chennai 53
Zhengzhou 53
Johannesburg 51
Brno 50
Regensburg 50
Toronto 47
Belo Horizonte 46
Brussels 45
Curitiba 44
Pune 43
Atlanta 41
Mexico City 41
Montreal 41
Baghdad 39
Da Nang 39
Tashkent 39
Boston 38
Phoenix 36
Lanzhou 35
Stockholm 35
Biên Hòa 34
Amsterdam 33
Manchester 31
Taizhou 30
Poplar 29
Amman 27
Haikou 27
Mumbai 27
Paris 27
Porto Alegre 27
Guayaquil 26
Norwalk 26
Orange 26
Totale 29.017
Salva come PNG Salva come JPEG
Nome #
Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis 316
Mesenchymal stromal cells (MSCs) induce ex vivo proliferation and erythroid commitment of cord blood haematopoietic stem cells (CB-CD34+ cells) 316
BACTERIAL BLOOD STREAM INFECTIONS NEGATIVELY IMPACT ON OUTCOME OF PATIENTS TREATED WITH ALLOGENEIC STEM CELL TRANSPLANTATION: 6 YEARS SINGLE-CENTRE EXPERIENCE 291
Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients 290
Circulating endothelial cell count: a reliable marker of endothelial damage in patients undergoing hematopoietic stem cell transplantation 268
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. 238
Zebrafish disease models in hematology: Highlights on biological and translational impact 233
A specific Toll-like receptor profile on T lymphocytes and values of monocytes correlate with bacterial, fungal, and cytomegalovirus infections in the early period of allogeneic stem cell transplantation 204
Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia 203
Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria 201
Comparative study on ATG-thymoglobulin versus ATG-fresenius for the graft-versus-host disease (GVHD) prophylaxis in allogeneic stem cell transplantation from matched unrelated donor: a single-centre experience over the contemporary years 198
Betaherpesvirus Reactivation and Toll-Like Receptor Expression After Allogeneic Stem Cell Transplantation. 188
Targeting HRASV12G Expression to the Zebrafish Early Hemogenic Progenitors Induces a Myeloproliferative Disorder by Repressing the Notch Pathway. 186
EXPRESSION OF TOLL-LIKE RECEPTORS ON PERIPHERAL BLOOD CELLS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: ONGOING RESULTS OF A PROSPECTIVE STUDY. 183
A Gene Panel NGS-Based Strategy for Genomic Characterization of Acute Myeloid Leukemias (AMLs) 177
Profile of Toll-Like Receptors on Peripheral Blood Cells in Relation to Acute Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation 176
Comparative Somatic Mutational Profiling of CD34+ Hematopoietic Precursors (HSC) and Circulating Endothelial Cells (CEC) in Patients with Primary Myelofibrosis (PMF) 172
Acute graft-versus-host disease and expression of Toll-like receptors on peripheral blood cells after allogeneic stem cell transplantation 171
TARGETING HRASV12G EXPRESSION TO THE ZEBRAFISH EARLY HEMOGENIC PROGENITORS INDUCES A MYELOPROLIFERATIVE DISORDER BY REPRESSING THE NOTCH PATHWAY. 170
Central Venous Catheter-Related Bloodstream Infection Caused by Brevibacterium casei in a Hematology Patient 169
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 168
Expression of Toll-Like Receptors on Peripheral Blood Cells After Allogeneic Stem Cell Transplantation: Results of a Prospective Study. 167
Multidimensional Geriatric Assessment for Elderly Patients (≥60 years) Submitted for Allogeneic Stem Cell Transplantation. a French (Paris) - Italian (Brescia) 10-Years Experience on 228 Patients 167
Advances in CMV Management: A Single Center Real-Life Experience 167
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 166
Clinical Care of Hematological Patients in a Bone Marrow Transplant Unit: Do Human Resources Influence Infection Incidence? 164
Development of BCR-ABL1 Transgenic Zebrafish Model Reproducing Chronic Myeloid Leukemia (CML) Like-Disease and Providing a New Insight into CML Mechanisms 162
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 159
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 159
High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review 157
Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year. 155
CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS 153
Identification of a Novel Mutation Predisposing to Familial AML and MDS Syndrome By a NGS Approach 153
MULTI-GENOTYPING OF MINOR HISTOCOMPATIBILITY ANTIGENS (MHAGS) IN ALLOGENEIC STEM CELL TRANSPLANTATION AND THEIR ROLE IN DETERMINING GRAFT VERSUS HOST DISEASE (GVHD) AND GRAFT VERSUS LEUKEMIA (GVL) EFFECT. 152
RT-qPCR versus Digital PCR: How Do They Impact Differently on Clinical Management of Chronic Myeloid Leukemia Patients? 152
Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia. 151
5-azacitidine five days/monthly schedule in symptomatic low-risk (IPSS: 0-1) myelodisplastic (MDS) patients. clinical and biological effects. 151
Targeting oncogene expression to endothelial cells induces proliferation of the myelo-erythroid lineage by repressing the notch pathway. 151
Central nervous system angiitis in Hodgkin's disease. 151
PARAMETERS OF PROTEIN METABOLISM AND THYROID FUNCTION AS PREDICTORS OF A SCORING SYSTEM FOR ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE 151
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment 151
Chitosan-Hydrogel Polymeric Scaffold Acts as an Independent Primary Inducer of Osteogenic Differentiation in Human Mesenchymal Stromal Cells 151
Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target? 150
Assessment of Liver Damage with Transient Hepatic Elastography (FIBROSCAN) in patients with chronic Graft-Versus-Host Disease. 148
Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner? 148
First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0/ MR4.0 Stable Molecular Response 148
Single Cell Analysis of Circulating Endothelial Cells in Allogeneic Hematopoietic Stem Cell Transplant; To Whom Do They Belong: Host or Donor? 148
Development of a cell culture model based on biocompatible polymeric scaffolds engineered with human Mesenchymal Stromal Cells (MSCs) for cartilage and bone regenerative therapy 147
Molecular and cytogenetic characterization of a new case of t(5;17)(q35;q21) variant acute promyelocytic leukemia 146
Ethical and legal issues in haematopoietic stem cells (HSC) donation: the controversial and problematic aspects in minors 145
Low dose AraC for Myelodysplastic Syndromes: is it still a current therapy ?. 144
Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing 144
CT-290: Clinical Frailty Scale as a Novel Tool to Evaluate Patients’ Eligibility for Allogeneic Stem Cell Transplant: A Single-Center Experience on 234 Patients >50 Years Old 144
Parameters of Protein Metabolism and Thyroid Function As Predictors in a Scoring System for Acute and Chronic Graft-Versus-Host Disease 141
Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives 141
A NEW PROMISING APPROACH TO PERFORM HLA TYPING IN A QUICKLY, SIMPLE AND ACCURATE WAY: THE PYROSEQUENCING 140
ANTI-CMV Immunoglobulins in Association with ANTI-CMV Drugs in Patients with Hematological Malignancies Submitted to Allogeneic STEM CELL Transplantation: A MULTI-Center Retrospective Experience 140
Advances in the treatment of monoclonal gammapathies: the emerging role of targeted therapy in plasma cell dyscrasias. 139
Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent 138
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 138
Parameters of Protein Metabolism and Thyroid Function As Predictors in a Scoring System for Acute and Chronic Graft-Versus-Host Disease 138
Evaluation of Circulating Endothelial Cells as Direct Marker of Endothelial Damage in Allo-Transplant Recipients at High Risk of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome 137
Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia. 137
Multidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients 137
Peripheral Blood WT1 Expression Predicts Relapse in AML Patients Undergoing Allogeneic Stem Cell Transplantation. 136
Comparative Study on Fresenius-ATG Versus Thymoglobuline-ATG for the Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation from Matched Unrelated Donor: A Single Center Experience on 76 Patients 136
Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients. 135
Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia 135
Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-kit positive acute myeloid leukemia. Results of an italian multicentric phase II study. 135
Platelet activation as a novel mechanism of atherothrombotic risk in chronic obstructive pulmonary disease. 134
Index of Bone Marrow Output and Imbalance of B-Lymphocyte Homeostasis before and after Transplantation Correlate Differently with Graft-Versus-Host Disease and Relapse 134
Digital PCR (Dpcr) a Step Forward to Detection and Quantification of Minimal Residual Disease (MRD) in Ph+/BCR-ABL1 Chronic Myeloid Leukemia (CML) 134
ETV6: A Candidate Gene for Predisposition to “Blend Pedigrees”? A Case Report from the NEXT-Famly Clinical Trial 133
AIDA: The italian way of treating acute promyelocytic leukemia (APL): final act . 133
Acute myeloid leukemia in the elderly: results obtained with conventional chemotherapy 132
Expression of Toll-like receptors on peripheral blood cells after allogeneic stem cell transplantation: ongoing results of a prospective study. 131
Prompt resolution of nasal aspergillosis with intranasal instillation of liposomal amphotericin-B (amBisome) and granulocyte transfusions 130
Urinary Protein Levels in Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) Predict Severe Disease Related Complications at Myeloma Progression 130
IN VIVO STUDY (MYCEC0617) OF CD34+-HSC AND CEC MUTATIONAL PROFILE FOR INVESTIGATING CELL ORIGIN AND PATHOGENESIS OF PRIMARY MYELOFIBROSIS (PMF) 130
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases 129
ACHIEVEMENT OF COMPLETE REMISSION WITH PONATINIB THERAPY FOR PHILADELPHIA ACUTE LYMPHOBLASTIC LEUKEMIA RELAPSED AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A CASE REPORT. 128
Case Report: Late Onset of Myelodysplastic Syndrome From Donor Progenitor Cells After Allogeneic Stem Cell Transplantation. Which Lessons Can We Draw From the Reported Case? 128
Four Drugs combination (Fludarabine, Cytarabine, Idarubicin, Etoposide) as induction therapy for newly diagnosed acute myeloid leukemia patients younger than 65 yrs: response and follow up of 127 patients. 128
Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study. 127
Allogeneic transplantation for patient with myelodisplastic sindromes: a single centre experience 127
Achievmento fo full donor chimerism and minimal residual disease clearance with early dasatinib therapy after intra-bone cord blood transplantation for Philadelphia positive acute lymphoblastic leukaemia: a case report 126
P1450: AUTOLOGOUS STEM CELL TRANSPLANTATION INDUCES HIGHER LEVEL OF EXHAUSTED T-CELLS IN DLBCL PATIENTS BEFORE LEUKAPHERESIS FOR CAR-T CELL THERAPY 125
ANTI-CMV IMMUNOGLOBULINS IN ASSOCIATION WITH ANTI-CMV DRUGS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES SUBMITTED TO ALLOGENEIC STEM CELL TRANSPLANTATION: A MULTI-CENTRE RETROSPECTIVE EXPERIENCE 125
Sequential monitoring of lymphocyte subsets and of T-and-B cell neogenesis indexes to identify time-varying immunologic profiles in relation to graft-versus-host disease and relapse after allogeneic stem cell transplantation 125
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years 124
DIGITAL PCR IN PH plus CHRONIC MYELOID LEUKEMIA PATIENTS FOR RECOGNITION OF "STABLE" DEEP MOLECULAR RESPONSE AND IDENTIFICATION OF BEST CANDIDATES TO TKI DISCONTINUATION 124
Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias 124
The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia – analysis of 848 patients. 123
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin. 123
WT1 Monitoring of Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukemia. 123
Safety and Efficacy of ATG-based GvHD prophylaxis in allogeneic stem cell transplantation for acute leukemia and myelodysplastic syndrome: a single center experience 123
Liposomal doxorubicin for the treatment of iatrogenic kaposi sarcoma following hematopoietic stem cell transplantation 123
Liposomal daunorubicin (DAUNOXOME) for treatment of relapsed meningeal acute myeloid leukemia. 122
Long term outcome of ph+ cml patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era. 122
Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Level. Comparison of Qpcr, d-PCR and CD26 Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR) 122
Totale 15.565
Salva come PNG Salva come JPEG
Categoria #
all - tutte 215.429
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 215.429
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.196 0 0 0 0 0 0 0 0 0 557 459 180
2021/20222.684 121 460 55 130 111 203 128 194 141 365 203 573
2022/20232.153 435 45 53 175 162 597 7 199 259 30 91 100
2023/20242.723 125 72 190 140 130 457 122 93 758 32 40 564
2024/20256.853 62 79 68 775 775 559 640 200 896 446 1.300 1.053
2025/202614.383 1.265 2.060 1.266 2.309 1.273 1.189 2.310 699 979 1.033 0 0
Totale 46.182